Results 51 to 60 of about 346 (112)

Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model. [PDF]

Menopause, 2021
Katri A, Reker D, Karsdal MA, Bay-Jensen AC, Henriksen K.   +4 more
europepmc   +1 more source

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity. [PDF]

J Obes Metab Syndr
Chung CW, Kim J.
europepmc   +1 more source

Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. [PDF]

Front Endocrinol (Lausanne)
Alhazmi A, le Roux CW.
europepmc   +1 more source

The roles of hepatokine and osteokine in liver-bone crosstalk: Advance in basic and clinical aspects. [PDF]

Front Endocrinol (Lausanne), 2023
Li Z, Wen X, Li N, Zhong C, Chen L, Zhang F, Zhang G, Lyu A, Liu J.   +8 more
europepmc   +1 more source

Dual Amylin and Calcitonin Receptor Agonists: A Novel Treatment for Obesity and Related Co-Morbidities [PDF]

, 2017
Gydesen, Sofie
core  

The effect of a Dual Amylin and Calcitonin Receptor Agonist (DACRA) on adipose tissue and energy expenditure [PDF]

, 2023
openaire  

El contracte del supulcre del cardenal Berenguer d'Anglesola [PDF]

, 1998
Valero Molina, Joan
core  

New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? [PDF]

Rev Endocr Metab Disord
Ryan DH.
europepmc   +1 more source

Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. [PDF]

Indian J Endocrinol Metab
Sidrak WR, Kalra S, Kalhan A.
europepmc   +1 more source

Brain Amylin Signaling, Feeding, and Reward. [PDF]

Compr Physiol
Mietlicki-Baase EG.
europepmc   +1 more source